FDA cleared zotarolimus-eluting stent for use in coronary arteries

Borden, William E.
March 2008
Endocrine Today;3/10/2008, Vol. 6 Issue 4, p36
The article reports that the U.S. Food and Drug Administration (FDA) has approved the zotarolimus-eluting stent for treating patients with narrowed coronary arteries. The stent had comparable safety and efficacy profile with a paclitaxel-eluting stent and a sirolimus-eluting stent during clinical trials. During the ENDEAVOR clinical program, its safety data has been collected and the study shows the stent demonstrated no additional incidents of myocardial infarction, noncardiac death or stent thrombosis.


Related Articles

  • FDA Actions: New Oral Antiplatelet Agent.  // Travel Medicine Advisor;Sep2009 Supplement, p1 

    The article announces the approval by the U.S. Food and Drug Aministration (FDA) of the use of prasugrel, a new oral anti platelet agent indicated for patients with acute coronary syndrome who are to be managed by angioplasty. The approval was based on a head-to-head study with clopidogrel that...

  • Esperion Therapeutics tests new drug compound. Henderson, Tom // Crain's Detroit Business;11/16/2009, Vol. 25 Issue 45, p2 

    The article reports that Plymouth, Michigan-based Esperion Therapeutics Inc. has been conducting a Phase 1 U.S. Food and Drug Administration clinical trial of a drug developed to treat dyslipidemia, an early-stage risk factor for coronary disease. The compound, named ETC-1002, prevents...

  • Stenting of the Unprotected Left Main Coronary Artery in a Nonagenarian Presenting with Recurrent Non-ST Elevation Myocardial Infarction. Raizada, Amol; Petrasko, Marian; Stys, Tomasz P.; Stys, Adam T. // South Dakota Medicine;Jul2014, Vol. 67 Issue 7, p265 

    Coronary artery disease (CAD) involving the left main (LM) artery has traditionally been considered an indication for coronary artery bypass surgery (CABG). With recent advances in the field of percutaneous coronary interventions (PCI), angioplasty and stenting of the unprotected' LM has been...

  • Drug-eluting stents increased risk for late cardiac death or myocardial infarction more than bare-metal stents. Pfisterer, M.; Brunner-La Rocca, H. P.; Buser, P. T. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p67 

    The article presents a study which examines the effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with coronary artery disease who discontinue anti-platelet therapy. Results revealed that DES lessen the risk of having major cardiac events. It is concluded that...

  • Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. Sung-Ho Her; Ki Dong Yoo; Chul-Soo Park; Dong-Bin Kim; Jong-Min Lee; Pum Joon Kim; Hee-Yeol Kim; Kiyuk Chang; Doo Soo Jeon; Wook Sung Chung; Ki-Bae Seung; Jae-Hyung Kim // Heart;Sep2011, Vol. 97 Issue 18, p1501 

    Objectives: To evaluate long-term clinical outcomes of overlapping heterogeneous drug-eluting stents (DES) compared with homogeneous DES. Design and setting The catholic medical centre coronary intervention database is a multicentre database of percutaneous coronary intervention with DES. This...

  • A Critical Appraisal of the Safety and Efficacy of Drug-Eluting Stents. Maluenda, G.; Lemesle, G.; Waksman, R. // Clinical Pharmacology & Therapeutics;May2009, Vol. 85 Issue 5, p474 

    Drug-eluting stents (DESs) have largely demonstrated their superiority to bare-metal stents (BMSs) with respect to in-stent restenosis. Since the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. They are used...

  • Drug-eluting stents: synchronous with late stent thrombosis? Crofskey, Samantha // Reactions Weekly;3/10/2007, Issue 1142, p3 

    Initial approval of drug-eluting stents (DES) was based on randomised, controlled trials that demonstrated a significantly greater reduction in the rates of target-vessel failure and risk of repeated revascularisation, or both, compared with bare-metal stents (BMS), at 9 months. Despite the...

  • Abbott's bioabsorbable stent seen working better than metal. YOFFEE, LYNN // Medical Device Daily;3/27/2009, Vol. 13 Issue 58, p1 

    The article focuses on the progress made by Abbott in creating a degradable metal stent for coronary artery disease. A clinical trial found that the stent made of polylactic acid not only does the job and then degrades, it also keeps the vessels healthier. According to Richard Rapoza, general...

  • TCT 2008 notebook.  // Medical Device Daily;10/14/2008, Vol. 12 Issue 218, p2 

    The article reports on data presented by Abbott from 30 patients in its clinical trial, demonstrating that its bioabsorbable drug-eluting stent (DES) successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years. It was noted that patients who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics